Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present BeiGene, Ltd. (NASDAQ: BGNE).

Full DD Report for BGNE

You must become a subscriber to view this report.


Recent News from (NASDAQ: BGNE)

Companies Outperforming the FANG+ Index under President Donald Trump
Palm Beach FL – September 7, 2018  – Under the administration of President Donald Trump, the U.S. stock market has been on an amazing growth run. Corporate earnings have been up, GDP growth has been strong, and unemployment is near historic lows. Tech shares have benefited mos...
Source: MarketNewsUpdates.com
Date: September, 07 2018 09:13
Your Cancer Highlight: Chi-Med Looks To Dominate Colorectal Cancer In China
Colorectal cancer ((CRC)) is one of the more difficult and controversial forms of cancer that we face. In America and many parts of Europe, the screening efforts we undertake allow us to catch a lot of cases in the earliest stages, where they can be effectively cured by a pretty simple procedu...
Source: SeekingAlpha
Date: September, 06 2018 08:00
BeiGene and SpringWorks Therapeutics inks deal to evaluate targeted combination therapy in advanced solid tumors
BeiGene (NASDAQ: BGNE ) and SpringWorks Therapeutics have entered into a global clinical collaboration to evaluate the safety, tolerability and preliminary efficacy of combining BeiGene’s investigational RAF dimer inhibitor, lifirafenib (BGB-283) and SpringWorks Therapeutics’...
Source: SeekingAlpha
Date: September, 06 2018 06:51
BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors
BeiGene’s RAF dimer inhibitor lifirafenib (BGB-283) and SpringWorks Therapeutics’ MEK inhibitor PD-0325901 to be studied in combination Combination approach will target RAS mutations common in many cancers Phase 1b clinical study expected to commence in the first...
Source: Business Wire
Date: September, 06 2018 06:00
BeiGene to Present Data on Anti-PD-1 Antibody Tislelizumab at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto
CAMBRIDGE, Mass. and BEIJING, China, Sept. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, to...
Source: GlobeNewswire
Date: September, 05 2018 17:05
BeiGene to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
CAMBRIDGE, Mass., and BEIJING, China, Sept. 04, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today anno...
Source: GlobeNewswire
Date: September, 04 2018 06:00
Your Daily Scoop: Anifrolumab Flunks, Aquestive Approved, Vertex's CRISPR Trial In Germany
Stocks in News: AZN, AQST AstraZeneca's anifrolumab flunks late-stage lupus study; shares down 1% premarket Discussion: AstraZeneca ( AZN ) announced failure of a Phase 3 trial of its anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (‘SLE...
Source: SeekingAlpha
Date: September, 03 2018 10:43
Week In Review: Nearly $1 Billion In Cross-Border China Biopharma Deals
Deals and Financings WeDoctor, Mason Group and Aldworth Management agreed to pay up to $510 million to acquire an 89.5% stake in Genea, an Australian fertility treatment company. Genea's assisted reproductive technologies are used in more than 600 clinics across 60 countries. Earlier this ye...
Source: SeekingAlpha
Date: September, 02 2018 12:16
BeiGene Announces Acceptance of New Drug Application for Anti-PD-1 Antibody Tislelizumab in Hodgkin's Lymphoma in China
BEIJING, China, and CAMBRIDGE, Mass., Aug. 31, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, to...
Source: GlobeNewswire
Date: August, 31 2018 06:00
Money flow stays positive in biotechs, XBI up 6% since last week
Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped  6%  since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the ...
Source: SeekingAlpha
Date: August, 27 2018 11:39

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-13143.00131.42143.91131.05351,071
2018-12-12137.45141.89145.20137.45721,244
2018-12-11139.02136.82141.74136.05368,811
2018-12-10137.20136.36139.95132.8374306,132
2018-12-07140.31137.59142.30135.05389,763

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1353,54076,89969.6238Short
2018-12-12111,479199,53055.8708Short
2018-12-1145,07781,95755.0008Short
2018-12-1028,24155,35551.0180Short
2018-12-0748,70385,92356.6821Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BGNE.


About BeiGene, Ltd. (NASDAQ: BGNE)

Logo for BeiGene, Ltd. (NASDAQ: BGNE)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: BGNE)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 09 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 04 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 30 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 16 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 04 2018
      Amendment to a previously filed Form 3
      Filing Type: 3/AFiling Source: edgar
      Filing Date: April, 04 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 28 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: February, 28 2018

       

       


      Daily Technical Chart for (NASDAQ: BGNE)

      Daily Technical Chart for (NASDAQ: BGNE)


      Stay tuned for daily updates and more on (NASDAQ: BGNE)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: BGNE)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BGNE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BGNE and does not buy, sell, or trade any shares of BGNE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/